V Arora

Summary

Affiliation: AVI BioPharma
Country: USA

Publications

  1. ncbi request reprint Redirection of drug metabolism using antisense technology
    V Arora
    Research and Development, AVI BioPharma Inc, Corvallis, OR 97333, USA
    Curr Opin Mol Ther 3:249-57. 2001
  2. ncbi request reprint Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats
    Vikram Arora
    AVI BioPharma, 4575 SW Research Way, Suite 200, Corvallis, Oregon 97333, USA
    J Pharm Sci 91:1009-18. 2002
  3. ncbi request reprint Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism
    Vikram Arora
    Research and Development, AVI BioPharma, Corvallis, Oregon 97333, USA
    Drug Metab Dispos 30:757-62. 2002
  4. ncbi request reprint Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics
    Vikram Arora
    Research and Development, AVI BioPharma, Inc, USA
    Curr Pharm Biotechnol 5:431-9. 2004
  5. ncbi request reprint Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats
    Vikram Arora
    AVI BioPharma, Corvallis, Oregon, USA
    Pharm Res 19:1465-70. 2002
  6. ncbi request reprint Transdermal delivery of phosphorodiamidate Morpholino oligomers across hairless mouse skin
    Angela K Pannier
    Department of Biological Systems Engineering, University of Nebraska, Lincoln, NE 68583 0726, USA
    Int J Pharm 275:217-26. 2004
  7. ncbi request reprint Antisense strategies for redirection of drug metabolism: using paclitaxel as a model
    Vikram Arora
    Research and Development, AVI BioPharma, Corvallis, OR, USA
    Methods Mol Med 106:273-92. 2005
  8. ncbi request reprint In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors
    Gayathri R Devi
    AVI BioPharma, Inc, Corvallis, Oregon and Oregon Health and Science University Cancer Institute, Portland, Oregon, USA
    Clin Cancer Res 11:3930-8. 2005
  9. ncbi request reprint A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity
    Carla A London
    AVI BioPharma Inc, 4575 SW Research Way, Suite 200, Corvallis, Oregon 97333, USA
    Cancer Gene Ther 10:823-32. 2003
  10. ncbi request reprint Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans
    Patrick L Iversen
    AVI BioPharma Inc, Corvallis, Oregon 97333, USA
    Clin Cancer Res 9:2510-9. 2003

Collaborators

  • Gayathri R Devi
  • TOMASZ BEER
  • R M Brand
  • D A Stein
  • Patrick L Iversen
  • Brinda Mahadevan
  • Angela K Pannier
  • Carla A London
  • Laura J Schild
  • Ainsley Weston
  • Clifford Pereira
  • Miriam C Poirier
  • Melissa L Cate
  • William M Baird
  • Channa Keshava
  • Harmanjatinder S Sekhon
  • A J Acker
  • David H Mason

Detail Information

Publications11

  1. ncbi request reprint Redirection of drug metabolism using antisense technology
    V Arora
    Research and Development, AVI BioPharma Inc, Corvallis, OR 97333, USA
    Curr Opin Mol Ther 3:249-57. 2001
    ..The use of antisense morpholino oligonucleotide strategies to target CYP enzymes may result in safer and more uniform therapeutic applications...
  2. ncbi request reprint Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats
    Vikram Arora
    AVI BioPharma, 4575 SW Research Way, Suite 200, Corvallis, Oregon 97333, USA
    J Pharm Sci 91:1009-18. 2002
    ..These studies highlight the potential for development of PMOs as orally administered therapeutic agents...
  3. ncbi request reprint Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism
    Vikram Arora
    Research and Development, AVI BioPharma, Corvallis, Oregon 97333, USA
    Drug Metab Dispos 30:757-62. 2002
    ..Finally, the cytocidal activity of cisplatin was not affected with AVI-4557 treatment in either cell type. These studies indicate AVI-4557 is an effective and specific inhibitor of CYP3A4 expression...
  4. ncbi request reprint Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics
    Vikram Arora
    Research and Development, AVI BioPharma, Inc, USA
    Curr Pharm Biotechnol 5:431-9. 2004
    ..This review will summarize the preclinical studies with PMOs on the road to their development as therapeutic agents with particular emphasis on in vivo biodistribution and pharmacokinetics...
  5. ncbi request reprint Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats
    Vikram Arora
    AVI BioPharma, Corvallis, Oregon, USA
    Pharm Res 19:1465-70. 2002
    ..To determine if dermal absorption of an antisense phosphorodiamidate Morpholino oligomers (PMO) can inhibit target gene expression in the liver in vivo...
  6. ncbi request reprint Transdermal delivery of phosphorodiamidate Morpholino oligomers across hairless mouse skin
    Angela K Pannier
    Department of Biological Systems Engineering, University of Nebraska, Lincoln, NE 68583 0726, USA
    Int J Pharm 275:217-26. 2004
    ..The presence of G-quartets correlated with better PMO penetration from a water vehicle. Overall, the data suggest that some oligomers and vehicles would be better for transdermal delivery and others for topical applications...
  7. ncbi request reprint Antisense strategies for redirection of drug metabolism: using paclitaxel as a model
    Vikram Arora
    Research and Development, AVI BioPharma, Corvallis, OR, USA
    Methods Mol Med 106:273-92. 2005
  8. ncbi request reprint In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors
    Gayathri R Devi
    AVI BioPharma, Inc, Corvallis, Oregon and Oregon Health and Science University Cancer Institute, Portland, Oregon, USA
    Clin Cancer Res 11:3930-8. 2005
    ..Data from both human studies indicated similar plasma concentration-time profile. These studies show PMO bioavailability in tumor tissue and establish the feasibility of using PMO targeting specific genes in human cancer clinical trials...
  9. ncbi request reprint A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity
    Carla A London
    AVI BioPharma Inc, 4575 SW Research Way, Suite 200, Corvallis, Oregon 97333, USA
    Cancer Gene Ther 10:823-32. 2003
    ..These data establish the feasibility of developing a site-directed, nontoxic antisense therapeutic agent for inhibiting local invasion and metastasis...
  10. ncbi request reprint Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans
    Patrick L Iversen
    AVI BioPharma Inc, Corvallis, Oregon 97333, USA
    Clin Cancer Res 9:2510-9. 2003
    ....
  11. ncbi request reprint Reduction in tamoxifen-induced CYP3A2 expression and DNA adducts using antisense technology
    Brinda Mahadevan
    Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, Oregon 97331, USA
    Mol Carcinog 45:118-25. 2006
    ..Overall the data suggest the utility of antisense technology in the redirection of TAM metabolism thereby lowering TAM genotoxicity in rat liver...